This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] Current approaches to target PDE4 to alleviate chronic inflammation associated with COPD are limited by dose-dependent side effects that are difficult to overcome
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1a
[0618] Example 1a: Preparation 1- ( 4-methoxybenzyl)-1H-pyrazol-5-amine
[0619] The compound is according to Bioorganic and medicinal chemistry letters (bioorganic and medicinal chemistry), 13， 1133-1136 (2003) described method is synthesized.
Embodiment 1b
[0620] Example 1b: Preparation of 1-ethyl-3-methyl-1H-pyrazol-5-amine
[0621] The compound according to Chem.Pharm.Bull. 52 (9), 1098-1104 (2004) described in the method for synthesis.
Embodiment 1c
[0622] Example 1c: Preparation of tetrahydro-2H-pyran-4-amine hydrochloride
[0623] The compound according to Tetrahedron letters, 42 , 4257-4259, (2001) described in the method for synthesis.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 / PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formura 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4 / PDE type 7 inhibitors are provided.
Description
field of invention [0001] The invention relates to type 4 phosphodiesterase (PDE), type 7 phosphodiesterase (PDE) and type 4 PDE / type 7 PDE dual inhibitors. [0002] The compounds disclosed herein are useful for treating, preventing, inhibiting or suppressing CNS diseases such as multiple sclerosis; various pathological conditions such as diseases affecting the immune system including AIDS, graft rejection, autoimmune diseases such as T-cell related Diseases such as rheumatoid arthritis; inflammatory diseases such as respiratory inflammatory diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases, Including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammatory diseases such as Crohn's disease, colitis, pancreatitis; and various types cancer, including leukemi...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More